Skip to main content
Assets
Moderna logo
MRNA.NASDAQ
Moderna
Health Care · Biotechnology

Biotechnology company pioneering messenger RNA therapeutics and vaccines, gained prominence with COVID-19 vaccine development.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Moderna.

Historical AI Opinions

Moderna, Inc. (MRNA.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 11 advisor reports and comparisons.

Updated on 3 May 2026Deep analysis 3 May 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated
J.P. Morgan AI advisor icon
Gemini 3 Pro

J.P. Morgan AI

The Titan Framework

Model rating

Buy

5-Year Return Est.

+349.0%

MRNA.NASDAQ does not currently pay dividends

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.-23.85114.78253.42392.05530.68Apr 2021Oct 2023Apr 2026Oct 2028May 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$52.2+15.0%
  • Smart money actively accumulates ahead of the September Phase 3 oncology data readout.
  • Q2 2026 earnings demonstrate the first signs of success in the $1.1B R&D cost-cutting mandate.
  • Ex-US combo-vaccine procurement contracts provide a solid revenue floor.
$65.2+43.7%
  • The convergence catalyst hits: Phase 3 INTerpath-001 data validates the 49% risk reduction in melanoma.
  • Violent short-covering and multiple expansion as the market prices in the oncology TAM.
  • The narrative officially shifts from 'busted COVID stock' to 'oncology juggernaut'.
$68.5+50.9%
  • Post-catalyst consolidation; momentum cools slightly but institutional support establishes a higher floor.
  • Q4 2026 earnings highlight accelerating ex-US sales of the mCombriax shot during winter.
  • US regulatory headwinds remain a persistent but increasingly isolated drag.
$74.0+63.0%
  • Pipeline expansion updates, specifically for NSCLC (lung cancer), show excellent clinical progression.
  • Cash burn trajectory is visibly improving, giving the street confidence in the 2028 breakeven target.
  • Potential bolt-on technology acquisition utilizes a small fraction of the cash pile.
$70.3+54.9%
  • A broader macro pullback hits the biotech sector as the Warsh regime maintains higher-for-longer rates.
  • Profit-taking occurs after a massive 12-month run.
  • Supply chain friction (helium/packaging) marginally impacts quarterly gross margins.
$78.7+73.4%
  • Regulatory filings for mRNA-4157 (cancer vaccine) are formally submitted to the FDA and EMA.
  • International winter respiratory season drives surprisingly robust cash generation.
  • Institutional ownership surges as the asset is de-risked.
$83.4+83.9%
  • Noise around potential FDA Advisory Committee (AdComm) meetings introduces moderate volatility.
  • M&A rumors circulate as the company signals readiness to scale commercial oncology infrastructure.
  • Global RSV market share stabilizes, though still trailing Pfizer/GSK.
$98.4+116.9%
  • The FDA officially approves mRNA-4157 for adjuvant melanoma. The empire is born.
  • Merck partnership synergies are activated, granting immediate global commercial distribution capability.
  • Analysts race to upgrade price targets, capitulating on the old bear thesis.
$106+134.3%
  • Initial launch metrics for the oncology asset show massive pent-up demand and high pricing power.
  • The personalized manufacturing infrastructure proves scalable and robust.
  • Competitors scramble, realizing they are structurally locked out of the neoantigen space.
$117+157.7%
  • Management formally declares cash-flow breakeven achieved, fully validating the 2025 strategic pivot.
  • The risk of shareholder dilution is permanently removed from the equation.
  • Moderna ascends to true 'Empire' status.
$134+196.4%
  • Phase 3 data for NSCLC (lung cancer) reads out positively, representing a dramatically larger TAM than melanoma.
  • The mRNA operating system is unequivocally proven to work across multiple solid tumors.
  • Valuations reflect a multi-decade growth runway.
$145+220.1%
  • The US political regime shifts, easing the hostile rhetoric and restoring favorable public health guidelines for mRNA.
  • US domestic revenue streams begin a structural recovery.
  • The geopolitical hedge strategy transitions into total global dominance.
$152+236.1%
  • The rare disease pipeline (e.g., Propionic Acidemia) begins to yield late-stage clinical successes.
  • Demonstrates that the LNP/mRNA delivery platform can address monogenic diseases, opening a third massive vertical.
  • Stable, low-volatility price appreciation sets in.
$163+259.6%
  • Oncology revenues are now compounding rapidly, entirely replacing the lost pandemic-era revenues with high-quality, durable earnings.
  • Gross margins expand as manufacturing efficiencies scale.
  • The legacy COVID anchor is entirely forgotten by the market.
$157+245.2%
  • Broader market rotation out of healthcare and into deep cyclicals causes a mild, technical correction.
  • Profit-taking by early institutional accumulators.
  • Underlying fundamentals remain pristine despite the price action.
$163+259.1%
  • Moderna flexes its acquisition machinery, executing a highly strategic bolt-on acquisition to acquire next-generation non-viral delivery platforms.
  • Deepens the competitive moat and prevents technological disruption.
  • Market applauds the disciplined use of capital.
$173+280.6%
  • Continued clinical dominance in adjuvant settings pushes out aspiring competitors.
  • The Herfindahl-Hirschman Index (HHI) for individualized cancer vaccines reflects absolute concentration of power in the Moderna/Merck duopoly.
  • Pricing power is absolute.
$181+299.6%
  • The winter respiratory season highlights the total global dominance of Moderna's trivalent (flu/COVID/RSV) shot.
  • Convenience factor completely erodes incumbent market share in the preventative space.
  • Steady cash flow generation funds massive internal expansion.
$194+327.6%
  • Oncology pipeline expands into early-stage settings, unlocking preventative cancer applications.
  • Massive operating leverage drives exceptional bottom-line profit growth.
  • The empire is structurally fortified against all known biological competitors.
$204+349.0%
  • Maturation into a mega-cap biopharma dynasty.
  • Management initiates a massive share repurchase program or institutes a dividend, rewarding long-term holders.
  • The transition from biotech startup to global healthcare sovereign is complete.
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

The 'True Price' trajectory demands that we view Moderna not as a fading vaccine vendor, but as an ascending biological operating system. Over the 5-year horizon, the structural decline in legacy COVID revenues will finally base, offset by the aggressive international rollout of the mCombriax flu/COVID combo. The ultimate value unlock arrives as the Merck-partnered oncology asset, mRNA-4157, clears Phase 3 trials and enters commercialization, fundamentally rewriting the company's DNA and multiple.

  • Phase 3 oncology data (late 2026) provides absolute validation of the mRNA platform in solid tumors.
  • International revenue dominance (currently 80%) successfully neutralizes the hostile US regulatory environment.
  • Ruthless execution of the $1.1B R&D cost-cutting mandate ensures the empire achieves cash-flow breakeven by 2028.
  • The $8.1B war chest allows for defensive independence and offensive M&A optionality.
  • The combination of oncology expansion, rare disease progress, and cash discipline drives sustained, multi-year multiple expansion.

2. Scenarios & Signals

2.1. Bull Case

In the bull case, absolute dominion is achieved. The Phase 3 oncology data vastly exceeds expectations, prompting the FDA to grant accelerated approvals across a broad spectrum of solid tumors. Moderna weaponizes its cash pile to acquire a cash-flowing commercial asset, accelerating breakeven.

  • mRNA-4157 establishes a monopolistic chokehold as the standard of care in adjuvant melanoma and NSCLC.
  • Global H5N1 (Bird Flu) panic triggers massive, high-margin sovereign procurement contracts.
  • Strategic M&A adds $1B+ in immediate, recurring non-vaccine revenue, destroying the bear thesis.
  • US political regime normalizes, entirely reopening the domestic market to mRNA therapeutics.

2.2. Bear Case

The bear case is catastrophic structural collapse. The oncology pipeline shatters as Phase 3 trials fail to replicate early efficacy, entirely wiping out the 'cancer premium' in the stock. US regulatory hostility deepens into outright bans.

  • INTerpath trials miss primary endpoints or trigger severe immunotoxicity signals, killing the oncology thesis.
  • Cash burn accelerates relentlessly, forcing highly dilutive capital raises in a punitive rate environment.
  • GSK and Pfizer ruthlessly exterminate mRESVIA, leaving Moderna entirely dependent on shrinking COVID sales.
  • Management panics, squandering the $8.1B cash pile on a desperate, value-destroying acquisition.

2.3. Behavioral Alpha Signals

Sentiment, repricing cycle, crowd narrative, catalyst, and macro alignment.

Expected Volatility Regime

LowModerateHighExtreme

Greed and Fear Index

-100 Fear0+100 Greed
-65

Cycle Position

The narrative is building and informed capital is paying attention.

EarlyAwareMomentumOvershootReversalCapit.StabilizeGROWING AWARENESS
Figure: Advisor position within the seven-stage market-recognition cycle. The highlighted point marks Growing Awareness.

What does Media Tell? (Crowd Consensus)

The noisy market treats Moderna as a crumbling pandemic empire, a one-hit wonder hopelessly trapped under the collapsing weight of its legacy COVID-19 revenues. Sell-side analysts are hyper-fixated on the cash burn, the disappointing RSV market share against GSK and Pfizer, and the overt hostility from US regulators. The prevailing narrative is anchored entirely in the rearview mirror, viewing the stock as a value trap rather than a platform company, entirely dismissing the massive oncology pipeline as a distant, high-risk fantasy.

What Crowds Get Wrong? (Alpha/Value Gap)

Here is the variant perception: The crowd is pricing Moderna as an infectious disease company losing a price war, while utterly ignoring its imminent ascension as an oncology juggernaut. The market assigns near-zero value to the Phase 3 individualized neoantigen therapy (INT) partnered with Merck, despite 5-year data demonstrating an incredible 49% sustained risk reduction in melanoma recurrence. Furthermore, the market ignores the fact that Moderna has successfully pivoted 80% of its revenue internationally, insulating itself from US regulatory chaos. The $8.1 billion cash fortress is a massive margin of safety that the crowd refuses to underwrite.

When will Value Gap Repricing Happen? (Repricing Catalyst)

The alpha gap will violently close with the release of the Phase 3 INTerpath-001 (melanoma) data, heavily anticipated in September 2026. A replication of the Phase 2b efficacy will force massive institutional capital to re-rate Moderna as a commercial oncology titan. Accumulation signals will appear via aggressive out-of-the-money call buying in late summer.

How is Asset Influenced by Macro Regime?

The macro winds are a brutal cross-current. The Warsh 'Sound Money' regime punishes long-duration, cash-burning biotech assets. However, Moderna’s massive $8.1B cash pile is the ultimate armor, completely insulating it from the refinancing death-spiral killing its smaller competitors. Geopolitical fragmentation actively accelerates sovereign demands for domestic bio-manufacturing, a trend Moderna is brilliantly exploiting ex-US.

3. Positive & Negative Factors, Risks & Opportunities

3.1. Base-Case Forces

Near-certain positive forces

Top Drivers / Tailwinds

Structural or operating forces that support this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).

Scroll to view all columns

Top Drivers / Tailwinds with asset-specific estimated impacts and thesis rationale
Driver / TailwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
Oncology Empire ValidationInnovation And Product+35%Not quantifiedThis is the ultimate siege engine. Moderna’s individualized neoantigen therapy (mRNA-4157), partnered with Merck, is demonstrating an unprecedented 49% sustained risk reduction in melanoma recurrence. The upcoming Phase 3 data will validate the mRNA platform as a foundational operating system for oncology, entirely shifting the company's TAM from low-margin seasonal vaccines to high-margin, monopolistic cancer therapeutics. We strongly believe this converts Moderna from a respiratory contender into an oncology juggernaut.
Fortress Balance SheetCapital Allocation+15%Not quantifiedWhile smaller biotech vassals suffocate under the Warsh 'Sound Money' regime and prohibitive capital costs, Moderna wields an $8.1 billion cash war chest. This is not just a buffer; it is an offensive weapon. It allows the empire to fund sprawling, multi-front Phase 3 trials without punitive shareholder dilution, and offers immense optionality to swallow subscale commercial targets when the consolidation cycle hits. Cash is power, and Moderna is armed to the teeth.
EX US Revenue PivotSector And Industry+12%Not quantifiedFaced with a hostile domestic regulatory apparatus, Moderna brilliantly executed a strategic retreat to friendlier territories. With international markets now driving 80% of revenue—evidenced by the massive Q1 2026 outperformance and European Commission approvals—the company has inoculated itself against US political volatility. This geographic diversification secures baseline cash flows while the broader platform matures.
Combo Vaccine MOATCompetitive Positioning+10%Not quantifiedConvenience is the ultimate switching cost. The European approval of mCombriax (the flu/COVID combined shot) establishes a structural barrier against competitors who can only offer single-pathogen defense. By monopolizing the patient's arm with a single, highly efficacious injection, Moderna forces incumbents to either match the combination or bleed market share. This is a textbook chokepoint strategy in preventative care.

Near-certain negative forces

Top Frictions / Headwinds

Expected frictions that can slow, cap, or damage this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).

Scroll to view all columns

Top Frictions / Headwinds with asset-specific estimated impacts and thesis rationale
Friction / HeadwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
Hostile US Regulatory SiegeRegulatory-15%Not quantifiedWe are deeply concerned by the domestic headwinds. HHS Secretary RFK Jr.'s overt hostility to mRNA technology, culminating in the loss of $500 million in federal funding, is a brutal regulatory tax. This ideological blockade drastically compresses the US TAM and forces Moderna to fight with one hand tied behind its back in its home territory. Until the political regime normalizes, the US market is a hostile wasteland.
RSV Vassal StatusCompetitive Positioning-12%Not quantifiedIn the RSV territory, Moderna is a vassal, not a titan. Launching mRESVIA late into an entrenched duopoly controlled by GSK and Pfizer has resulted in humiliatingly low market capture ($10M in Q3 2025). The narrowed CDC guidelines further restricted the beachhead. Moderna is bleeding resources in a battle it has already lost to incumbents with deeper commercial distribution chokepoints.
Pandemic Anchor DRAGSector And Industry-10%Not quantifiedThe ghost of the COVID-19 pandemic continues to haunt the income statement. As global immunity normalizes and populations experience severe vaccine fatigue, the rapid decay of legacy Spikevax revenues creates a massive top-line headwind. This forces the company to outrun a collapsing base just to show flat revenue, masking the underlying growth of the new pipeline.
Structural CASH BURNOperational Efficiency-8.0%Not quantifiedEven with the newly announced austerity measures, sustaining 35+ clinical programs demands a staggering capital burn rate. In a high-inflation, high-rate macro environment where duration is heavily penalized, Moderna's timeline to profitability (2028) is dangerously long. Every quarter of multi-billion dollar R&D burn erodes the fortress balance sheet, leaving less ammunition for offensive M&A.

3.2. Risks & Opportunities

Plausible downside scenarios

Tail Risks

Less likely downside scenarios that could materially hurt the outcome if they occur.

Scroll to view all columns

Tail risks with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
Phase 3 Oncology Collapse25%-45%This is the existential threat. If the Phase 3 INTerpath trials fail to meet primary endpoints or exhibit unforeseen toxicity, the foundational pillar of Moderna's forward valuation shatters. The market is already pricing in a baseline level of success for mRNA-4157; a failure here would irreparably break the growth narrative and trigger a catastrophic capitulation.
US Regulatory Excommunication20%-30%Should the hostile domestic political regime escalate from defunding mRNA research to outright restricting or banning the platform's use on dubious safety claims, Moderna would lose access to the most lucrative healthcare market on Earth. This would cripple commercial launches and force an entire reliance on the fractured European and Asian markets.

Plausible upside scenarios

Tail Opportunities

Less likely upside scenarios that could materially improve the outcome if they occur.

Scroll to view all columns

Tail opportunities with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
Accelerated Oncology Approval40%+40%If the highly anticipated Phase 3 INTerpath-001 (melanoma) data expected in September 2026 mirrors the staggering 49% risk reduction seen in Phase 2b, the FDA could grant accelerated approval. This singular event would violently instantly reprice Moderna from a struggling infectious disease vendor into a premier, commercial-stage oncology empire, unlocking a multi-billion dollar TAM overnight.
Transformative M&a Strike35%+25%With an $8.1 billion war chest, Moderna has the capacity to execute a ruthless, opportunistic acquisition of a distressed, commercial-stage biotech peer. Buying immediate, accretive revenue would bridge the gap to the 2028 cash-flow break-even target, instantly diversifying the top line and silencing Wall Street critics obsessing over the COVID revenue cliff.

5. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 72,793Thinking Tokens: 4,921Response Tokens: 5,283Total Tokens: 82,997
Researcher modeExternal search used

External web search was used. The immutable publication retained the search terms, but no source URLs were recorded.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    inmemory_base_placeholders__latest_eod_close_price_with_stats__var2

  2. 02

    Global context in this run

    Used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Subject context

    Equity-specific subject and market context

  5. 05

    Global context

    Standard global market and cross-asset context

  6. 06

    Task framework

    Standard investment-forecast task guidelines

  7. 07
    J.P. Morgan AI advisor icon

    Advisor framework

    Jp Morgan The Titan

  8. 08

    Forecast output requested

    Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

03

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

File size
90.8K bytes
Words
12.8K words
Characters
90.8K characters

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From FileDateStatus
DeepSeek shock and AI economics reset2025-01-27OPEN ENDED TREND
US tariff regime escalation and trade-system rupture2025-02-01ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold2025-09-17ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal ReserveUS Bureau of Labor StatisticsUS Bureau of Economic AnalysisUS TreasuryUS Energy Information AdministrationReuters WorldAssociated Press World NewsBBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market Context through 2026-04-10

Download Archived Snapshot

Coverage 2026-01-01 to 2026-04-10 · Knowledge cutoff 2026-04-10

File size
73.5K bytes
Words
9.8K words
Characters
73.5K characters

This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-04-10.

It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.

Top 3 market shifts from 2026 Year-to-Date Global Market Context through 2026-04-10
Top 3 Market Shifts From FileDateStatus
The Iran and Strait of Hormuz conflict shocked energy markets2026-02-28STARTED AND ONGOING
U.S. monetary policy entered the Warsh transition2026-01-30STARTED AND ACTIVE POLICY TRANSITION
Agentic AI and infrastructure spending kept expanding2026-01-01OPEN ENDED

Representative Sources of the Context File

Federal ReserveU.S. Bureau of Labor StatisticsU.S. Bureau of Economic AnalysisU.S. TreasuryU.S. Energy Information AdministrationReutersAssociated PressBBC News

And more sources from the retained context package.

02

Fundamental context

annual: 0 periods; quarterly: 0 periods

Currencies cited: USD (quote USD).

Search terms retained

  1. 1."Moderna" RSV vaccine approval mRESVIA market share
  2. 2."Moderna" INT Merck Phase 3 melanoma mRNA-4157
  3. 3."Moderna" acquisition history M&A 2025 2026
  4. 4."Moderna" market share mRNA vaccines 2025 2026

Search terms were retained, but this immutable publication does not contain source URLs for the run.

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.